Key statistics
On Friday, Iovance Biotherapeutics Inc (IOVA:NMQ) closed at 2.23, 36.10% above the 52 week low of 1.64 set on May 19, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.39 |
---|---|
High | 2.48 |
Low | 2.22 |
Bid | 2.23 |
Offer | 2.29 |
Previous close | 2.34 |
Average volume | 18.56m |
---|---|
Shares outstanding | 333.93m |
Free float | 276.56m |
P/E (TTM) | -- |
Market cap | 781.41m USD |
EPS (TTM) | -1.23 USD |
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
More ▼
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
- Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
- Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics to Present at Upcoming Conference
- The Journal of Clinical Oncology Publishes Five-year Analysis of Amtagvi® (lifileucel) in Patients with Advanced Melanoma
- Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting
- Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025
More ▼